TD Waterhouse Canada Inc. Acquires 109,142 Shares of Illumina, Inc. $ILMN

TD Waterhouse Canada Inc. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 599.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,357 shares of the life sciences company’s stock after buying an additional 109,142 shares during the period. TD Waterhouse Canada Inc. owned about 0.08% of Illumina worth $33,892,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ILMN. Baker Tilly Wealth Management LLC increased its position in Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after acquiring an additional 42 shares during the period. Elevation Wealth Partners LLC raised its stake in shares of Illumina by 19.7% during the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock valued at $80,000 after acquiring an additional 48 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Illumina by 1.5% during the third quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the life sciences company’s stock worth $1,103,000 after purchasing an additional 61 shares during the period. Meeder Advisory Services Inc. lifted its holdings in shares of Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the period. Finally, Gabelli Funds LLC lifted its holdings in shares of Illumina by 2.0% during the first quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company’s stock worth $616,000 after purchasing an additional 100 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

NASDAQ:ILMN opened at $262.54 on Friday. The company has a market capitalization of $39.64 billion, a PE ratio of 48.98, a P/E/G ratio of 3.72 and a beta of 1.41. The company has a 50 day simple moving average of $234.53 and a two-hundred day simple moving average of $186.01. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a fifty-two week low of $94.00 and a fifty-two week high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. The trade was a 13.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and raised their target price for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. Guggenheim raised their target price on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $225.94.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.